US FDA grants fast track designation to Kyverna Therapeutics' KYV─101 to treat lupus nephritis

US FDA grants fast track designation to Kyverna Therapeutics' KYV─101 to treat lupus nephritis Kyverna Therapeutics (Kyverna), a cell therapy company with the ... Lees verder

Bron:

Pharmamarketeer